Why the study?
Prasugrel and ticagrelor show greater efficacy than clopidogrel in ACS generally but have not shown better efficacy in Korean patients, prompting evaluation in high-risk patients with MI and diabetes.
Does prasugrel or ticagrelor reduce the composite of cardiac death, recurrent MI, or stroke compared to clopidogrel in Korean patients with MI and diabetes undergoing PCI?
Population
3985 patients with MI and diabetes undergoing PCI in Korea
Comparison
Prasugrel/ticagrelor vs clopidogrel
Design
Registry-based propensity score-matched observational study
Follow-up
1-year
Authors
Loading...
Prasugrel/ticagrelor may not outperform clopidogrel in Korean MI patients with diabetes; leaves open whether potent P2Y12 inhibitors benefit this population.
Does prasugrel or ticagrelor reduce the composite of cardiac death, recurrent MI, or stroke compared to clopidogrel in Korean patients with MI and diabetes undergoing PCI?
In Korean patients with MI and diabetes undergoing PCI, potent P2Y12 inhibitors (prasugrel/ticagrelor) did not improve ischemic outcomes but significantly increased major bleeding compared to clopidogrel.
Ahn et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: